8-K: Accuray Q1 FY26: Revenue Down, New CEO, Restructuring

Accuray reports a 7% decline in Q1 FY26 net revenue to $93.9 million, alongside a net loss of $21.7 million, while announcing a new CEO and restructuring efforts.

Summary

• Total net revenue for the first quarter of fiscal 2026 was $93.9 million, a 7% decrease compared to $101.5 million in the prior fiscal year first quarter.
• Product revenue decreased by 23% to $37.2 million, while service revenue increased by 7% to $56.8 million.
• Gross profit was $26.5 million, representing 28.3% of total net revenue, down from 33.9% in the prior fiscal year first quarter, primarily due to geographic sales mix and joint venture accounting.
• Operating expenses increased by 3% to $37.9 million, including $2.4 million in restructuring charges and $0.4 million in one-time post-close financing expenses.
• Net loss significantly widened to $21.7 million, or $0.18 per share, compared to a net loss of $4.0 million, or $0.04 per share, in the prior fiscal year first quarter.
• Adjusted EBITDA was a loss of $4.1 million, a decline from a positive $3.1 million in the prior fiscal year first quarter.
• Gross product orders decreased to $39.6 million from $55.4 million in the prior fiscal year first quarter, with order backlog at $395.7 million, approximately 16% lower year-over-year.
• Cash, cash equivalents, and short-term restricted cash increased by $5.9 million from June 30, 2025, to $63.9 million as of September 30, 2025.
• Steve La Neve was appointed President and Chief Executive Officer on October 20, 2025, succeeding Suzanne Winter, who will retire but remain in an advisory role through November 2025.
• Steven F. Mayer was appointed Transformation Board Sponsor to lead strategic, organizational, cultural, and operational initiatives.
• A restructuring plan was initiated, resulting in $2.8 million in charges, including $1.5 million in severance and $1.3 million in consulting costs.
• The Accuray Stellar* Solution, a configuration of the Radixact Treatment Delivery System, was introduced for the U.S. market.
• A memorandum of understanding was signed with the University of Wisconsin School of Medicine and Public Health to advance online adaptive radiotherapy.
• Fiscal year 2026 financial guidance was reaffirmed, with total net revenue expected between $471 million and $485 million, and Adjusted EBITDA between $31 million and $35 million.

Sentiment

Score: 3

Explanation: The significant decline in revenue, widening net loss, negative adjusted EBITDA, and reduced order backlog indicate a challenging quarter. While management changes and new product introductions are positive, the overall financial performance is weak, despite reaffirming full-year guidance.

Positives

• Service revenue increased by 7% to $56.8 million in the first quarter of fiscal 2026.
• Cash, cash equivalents, and short-term restricted cash increased by $5.9 million sequentially to $63.9 million as of September 30, 2025.
• The Accuray Stellar* Solution, a new configuration of the Radixact Treatment Delivery System, was introduced for the U.S. market.
• A memorandum of understanding was signed with the University of Wisconsin School of Medicine and Public Health to advance online adaptive radiotherapy.
• The book-to-bill ratio remained strong at 1.1 in the first quarter of fiscal 2026.
• Full fiscal year 2026 financial guidance for total net revenue and Adjusted EBITDA was reaffirmed.

Negatives

• Total net revenue decreased by 7% to $93.9 million in the first quarter of fiscal 2026.
• Product revenue experienced a significant 23% decrease to $37.2 million.
• Gross profit margin declined to 28.3% from 33.9% in the prior fiscal year first quarter, impacted by geographic sales mix and joint venture accounting.
• Net loss widened substantially to $21.7 million ($0.18 per share) from $4.0 million ($0.04 per share) in the prior fiscal year first quarter.
• Adjusted EBITDA shifted to a loss of $4.1 million from a positive $3.1 million in the prior fiscal year first quarter.
• Gross product orders decreased by 28.5% to $39.6 million.
• Order backlog decreased by approximately 16% year-over-year to $395.7 million.
• Operating expenses increased by 3%, including $2.8 million in restructuring charges and $0.4 million in one-time post-close financing expenses.

Risks

• The global macroeconomic environment may affect operations, customers, and suppliers.
• Disruptions to the supply chain, including increased logistics costs, could impact the company.
• Achieving widespread market acceptance of products remains a challenge.
• Substantial outstanding indebtedness and the ability to maintain compliance with financial covenants related to debt pose a risk.
• Enhanced international tariffs could negatively affect the company.
• The ability to realize the expected benefits of the China joint venture and other partnerships is uncertain.
• Risks are inherent in international operations.
• Maintaining or increasing gross margins on product sales and services may be difficult.
• Delays in regulatory approvals or the development or release of new offerings could occur.
• The ability to meet covenants under credit facilities is a concern.
• Converting backlog to revenue may face challenges.

Future Outlook

The company is reaffirming its financial guidance for fiscal year 2026, expecting total net revenue in the range of $471 million to $485 million and Adjusted EBITDA in the range of $31 million to $35 million.

Management Comments

• "As the new CEO of Accuray, I have a tremendous amount of respect for what our radiotherapy systems can do to improve cancer patients lives for the better." Steve La Neve
• "While our first quarter results were soft, we were pleased to see continued expansion of our CyberKnife and Radixact Systems into new hospitals and markets, and we are excited about the introduction of Accuray Stellar and its potential in the U.S., where it is currently available for sale." Steve La Neve

Industry Context

Accuray operates in the specialized field of radiation therapy for cancer treatment. The introduction of the Accuray Stellar Solution and the memorandum of understanding with the University of Wisconsin highlight ongoing innovation and strategic partnerships aimed at advancing adaptive radiotherapy. These efforts align with broader industry trends focused on enhancing precision, efficiency, and personalized care in oncology. Despite these advancements, the 'soft' first-quarter results suggest the company is navigating a challenging market environment, potentially facing competitive pressures or broader economic headwinds impacting capital equipment purchases in healthcare.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are mentioned in the filing for direct industry comparison.

Management Changes

Corporate Governance

Related Party Transactions

• Joint venture accounting adversely impacted product gross margins during the quarter.
• A net deferral of $1.1 million in Q1 FY26 margin is largely a result of a higher mix of shipments to the China joint venture, reflecting ongoing transactions with this related party.

Stakeholder Impact

• Shareholders: Negative impact due to significant net loss, decreased revenue, and reduced backlog, potentially impacting share price. Reaffirmed guidance might offer some stability.
• Employees: Impacted by the restructuring plan, including severance-related costs, suggesting potential job reductions or reassignments.
• Customers: Potential positive impact from new product introductions like Accuray Stellar and advancements in adaptive radiotherapy through the University of Wisconsin MOU.
• Creditors: The company has 'substantial outstanding indebtedness' and needs to 'maintain compliance with financial covenants related to its debt,' which could be a concern given the financial performance.

Next Steps

• Steve La Neve, the new CEO, will lead the company's planning and execution of strategic, organizational, cultural, and operational initiatives.
• Suzanne Winter will remain in an advisory role through the end of November 2025 to assist with the transition.
• The company will continue to execute its initiated restructuring plan aimed at reducing costs and streamlining operations.
• Accuray will host a conference call on November 5, 2025, to discuss the first quarter fiscal 2026 results and recent corporate developments.

Key Dates

Recommendation

While the financial results for the quarter are significantly worse than the prior year, the company has taken decisive action with a new CEO and a restructuring plan. The reaffirmation of full-year guidance suggests management believes in a turnaround or stabilization. The introduction of new products and strategic partnerships also offers future potential. However, the current financial performance and reduced backlog warrant caution, making a 'hold' position appropriate to observe the effectiveness of the new leadership and strategic initiatives.

Keywords

Accuray, ARAY, financial results, Q1 FY26, earnings, radiation therapy, oncology, medical devices, CyberKnife, Radixact, Accuray Stellar, restructuring, CEO change, net revenue, net loss, adjusted EBITDA, order backlog, corporate governance